Based on the available literature, our objective was to provide an overview and compare GLP-1 RAs and SGLT inhibitors regarding mechanisms of action, potential adverse effects, and ability to modify or prevent cardiovascular comorbidities associated with T2DM. The gene discussed is GCG; the disease is type 2 diabetes mellitus.